Translational Models in Glioma Immunotherapy Research

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2023 Jun 27

PMID 37366911

Authors

Alexander L Ren

Janet Y Wu

Si Yeon Lee

Michael Lim

Affiliations

Soon will be listed here.

Abstract

Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However, clinical trials of various immunotherapeutic modalities have not yielded significant improvements in patient survival. Preclinical models for glioma research should faithfully represent clinically observed features regarding glioma behavior, mutational load, tumor interactions with stromal cells, and immunosuppressive mechanisms. In this review, we dive into the common preclinical models used in glioma immunology, discuss their advantages and disadvantages, and highlight examples of their utilization in translational research.

Citing Articles

Immunocompetent murine glioblastoma stem-like cell models exhibiting distinct phenotypes.

Kardani K, Ghouse S, Din Abdul Jabbar M, Rajasubramanian N, Sanchez Gil J, Stemmer-Rachamimov A Neurooncol Adv. 2025; 7(1):vdae215.

PMID: 39896074 PMC: 11783566. DOI: 10.1093/noajnl/vdae215.

Bridging the gap between tumor and disease: Innovating cancer and glioma models.

Cirigliano S, Fine H J Exp Med. 2024; 222(1).

PMID: 39626263 PMC: 11614461. DOI: 10.1084/jem.20220808.

Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.

Mikolajewicz N, Tatari N, Wei J, Savage N, Farias A, Dimitrov V Acta Neuropathol. 2024; 148(1):74.

PMID: 39592459 PMC: 11599368. DOI: 10.1007/s00401-024-02831-w.

Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma.

Shao G, Cui X, Wang Y, Luo S, Li C, Jiang Y CNS Neurosci Ther. 2024; 30(7):e14791.

PMID: 38997808 PMC: 11245405. DOI: 10.1111/cns.14791.

The tumour microenvironment, treatment resistance and recurrence in glioblastoma.

White J, White M, Wickremesekera A, Peng L, Gray C J Transl Med. 2024; 22(1):540.

PMID: 38844944 PMC: 11155041. DOI: 10.1186/s12967-024-05301-9.

References

Hicks W, Bird C, Traylor J, Shi D, El Ahmadieh T, Richardson T . Contemporary Mouse Models in Glioma Research. Cells. 2021; 10(3). PMC: 8004772. DOI: 10.3390/cells10030712. View

Ladomersky E, Zhai L, Lenzen A, Lauing K, Qian J, Scholtens D . IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018; 24(11):2559-2573. PMC: 5984675. DOI: 10.1158/1078-0432.CCR-17-3573. View

Khan S, Desai R, Coxon A, Livingstone A, Dunn G, Petti A . Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors. J Immunother Cancer. 2022; 10(12). PMC: 9772691. DOI: 10.1136/jitc-2022-005293. View

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Ni H, Spellman S, Jean W, Hall W, Low W . Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol. 2001; 51(1):1-9. DOI: 10.1023/a:1006452726391. View

Kim J, Patel M, Mangraviti A, Kim E, Theodros D, Velarde E . Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res. 2016; 23(1):124-136. PMC: 5735836. DOI: 10.1158/1078-0432.CCR-15-1535. View

Bender A, Collier L, Rodriguez F, Tieu C, Larson J, Halder C . Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. Cancer Res. 2010; 70(9):3557-65. PMC: 2862088. DOI: 10.1158/0008-5472.CAN-09-4674. View

Ausman J, Shapiro W, Rall D . Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res. 1970; 30(9):2394-400. View

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber S . T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018; 24(17):4175-4186. PMC: 6081269. DOI: 10.1158/1078-0432.CCR-17-1846. View

10.

Binello E, Qadeer Z, Kothari H, Emdad L, Germano I . Stemness of the CT-2A Immunocompetent Mouse Brain Tumor Model: Characterization In Vitro. J Cancer. 2012; 3:166-74. PMC: 3328782. DOI: 10.7150/jca.4149. View

11.

Pellegatta S, Poliani P, Corno D, Grisoli M, Cusimano M, Ubiali F . Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res. 2006; 28(5):527-31. DOI: 10.1179/016164106X116809. View

12.

Talmadge J, Singh R, Fidler I, Raz A . Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007; 170(3):793-804. PMC: 1864878. DOI: 10.2353/ajpath.2007.060929. View

13.

Hubert C, Rivera M, Spangler L, Wu Q, Mack S, Prager B . A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res. 2016; 76(8):2465-77. PMC: 4873351. DOI: 10.1158/0008-5472.CAN-15-2402. View

14.

Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty S, Teichmann L . Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014; 32(4):364-72. PMC: 4017589. DOI: 10.1038/nbt.2858. View

15.

Chen Z, Peng P, Zhang X, Mania-Farnell B, Xi G, Wan F . Advanced Pediatric Diffuse Pontine Glioma Murine Models Pave the Way towards Precision Medicine. Cancers (Basel). 2021; 13(5). PMC: 7961799. DOI: 10.3390/cancers13051114. View

16.

Shingu T, Ho A, Yuan L, Zhou X, Dai C, Zheng S . Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet. 2016; 49(1):75-86. PMC: 5453714. DOI: 10.1038/ng.3711. View

17.

Noffsinger B, Witter A, Sheybani N, Xiao A, Manigat L, Zhong Q . Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner. J Neurooncol. 2021; 154(2):145-157. PMC: 9277914. DOI: 10.1007/s11060-021-03822-7. View

18.

Agliardi G, Liuzzi A, Hotblack A, De Feo D, Nunez N, Stowe C . Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021; 12(1):444. PMC: 7815781. DOI: 10.1038/s41467-020-20599-x. View

19.

Tran T, Uhl M, Ma J, Janssen L, Sriram V, Aulwurm S . Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol. 2007; 9(3):259-70. PMC: 1907409. DOI: 10.1215/15228517-2007-010. View

20.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View